Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Herpes Labialis Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Valacyclovir
  • 1.3.3 Aciclovir
  • 1.3.4 Famciclovir
  • 1.3.5 Docosanol
  • 1.3.6 Other
• 1.4 Market Segment by Application
  • 1.4.1 Global Herpes Labialis Drugs Market Share by Application (2019-2025)
  • 1.4.2 External Use
  • 1.4.3 Oral
  • 1.4.4 Injection
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Herpes Labialis Drugs Market Size
  • 2.1.1 Global Herpes Labialis Drugs Revenue 2014-2025
  • 2.1.2 Global Herpes Labialis Drugs Sales 2014-2025
• 2.2 Herpes Labialis Drugs Growth Rate by Regions
  • 2.2.1 Global Herpes Labialis Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Herpes Labialis Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Herpes Labialis Drugs Sales by Manufacturers
  • 3.1.1 Herpes Labialis Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Herpes Labialis Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Herpes Labialis Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Herpes Labialis Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Herpes Labialis Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Herpes Labialis Drugs Price by Manufacturers
• 3.4 Key Manufacturers Herpes Labialis Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Herpes Labialis Drugs Market
• 3.6 Key Manufacturers Herpes Labialis Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Valacyclovir Sales and Revenue (2014-2019)
  • 4.1.2 Aciclovir Sales and Revenue (2014-2019)
  • 4.1.3 Famciclovir Sales and Revenue (2014-2019)
  • 4.1.4 Docosanol Sales and Revenue (2014-2019)
  • 4.1.5 Other Sales and Revenue (2014-2019)
• 4.2 Global Herpes Labialis Drugs Sales Market Share by Type
• 4.3 Global Herpes Labialis Drugs Revenue Market Share by Type
• 4.4 Herpes Labialis Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Herpes Labialis Drugs Sales by Application

6 United States

• 6.1 United States Herpes Labialis Drugs Breakdown Data by Company
• 6.2 United States Herpes Labialis Drugs Breakdown Data by Type
• 6.3 United States Herpes Labialis Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Herpes Labialis Drugs Breakdown Data by Company
• 7.2 European Union Herpes Labialis Drugs Breakdown Data by Type
• 7.3 European Union Herpes Labialis Drugs Breakdown Data by Application

8 China

• 8.1 China Herpes Labialis Drugs Breakdown Data by Company
• 8.2 China Herpes Labialis Drugs Breakdown Data by Type
• 8.3 China Herpes Labialis Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Herpes Labialis Drugs Breakdown Data by Company
• 9.2 Rest of World Herpes Labialis Drugs Breakdown Data by Type
• 9.3 Rest of World Herpes Labialis Drugs Breakdown Data by Application
• 9.4 Rest of World Herpes Labialis Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Herpes Labialis Drugs Sales by Countries
  • 9.4.2 Rest of World Herpes Labialis Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 GSK
  • 10.1.1 GSK Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.1.4 Herpes Labialis Drugs Product Introduction
  • 10.1.5 GSK Recent Development
• 10.2 Novartis
  • 10.2.1 Novartis Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.2.4 Herpes Labialis Drugs Product Introduction
  • 10.2.5 Novartis Recent Development
• 10.3 Teva
  • 10.3.1 Teva Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.3.4 Herpes Labialis Drugs Product Introduction
  • 10.3.5 Teva Recent Development
• 10.4 Mylan
  • 10.4.1 Mylan Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.4.4 Herpes Labialis Drugs Product Introduction
  • 10.4.5 Mylan Recent Development
• 10.5 Cadila
  • 10.5.1 Cadila Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.5.4 Herpes Labialis Drugs Product Introduction
  • 10.5.5 Cadila Recent Development
• 10.6 Apotex
  • 10.6.1 Apotex Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.6.4 Herpes Labialis Drugs Product Introduction
  • 10.6.5 Apotex Recent Development
• 10.7 Daewoong Pharmaceutical
  • 10.7.1 Daewoong Pharmaceutical Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.7.4 Herpes Labialis Drugs Product Introduction
  • 10.7.5 Daewoong Pharmaceutical Recent Development
• 10.8 Livzon
  • 10.8.1 Livzon Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.8.4 Herpes Labialis Drugs Product Introduction
  • 10.8.5 Livzon Recent Development
• 10.9 Luoxin
  • 10.9.1 Luoxin Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.9.4 Herpes Labialis Drugs Product Introduction
  • 10.9.5 Luoxin Recent Development
• 10.10 Med shine
  • 10.10.1 Med shine Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Herpes Labialis Drugs
  • 10.10.4 Herpes Labialis Drugs Product Introduction
  • 10.10.5 Med shine Recent Development
• 10.11 Bayer (Campho Phenique)
• 10.12 Blistex
• 10.13 Kelun Group
• 10.14 Hikma
• 10.15 Haiwang
• 10.16 Carmex
• 10.17 Cipher

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Herpes Labialis Drugs Sales Channels
  • 11.2.2 Herpes Labialis Drugs Distributors
• 11.3 Herpes Labialis Drugs Customers

12 Market Forecast

• 12.1 Global Herpes Labialis Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Herpes Labialis Drugs Sales Forecast by Type
• 12.3 Global Herpes Labialis Drugs Sales Forecast by Application
• 12.4 Herpes Labialis Drugs Forecast by Regions
  • 12.4.1 Global Herpes Labialis Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Herpes Labialis Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

In 2019, the market size of Herpes Labialis Drugs is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Herpes Labialis Drugs.

This report studies the global market size of Herpes Labialis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Herpes Labialis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher

Market Segment by Product Type
Valacyclovir
Aciclovir
Famciclovir
Docosanol
Other

Market Segment by Application
External Use
Oral
Injection

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Herpes Labialis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Herpes Labialis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Herpes Labialis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025